Company Performance Metrics
Extentus Pharma is a clinical-stage pharmaceutical and biotechnology company that develops long-acting injectable drug delivery platforms. The company reformulates existing small-molecule drugs using its proprietary solid drug nanoparticle technology to improve bioavailability and convert frequent oral dosing into infrequent injectable regimens.
Extentus Pharma concentrates on therapies for infectious diseases, including malaria, hepatitis C and latent tuberculosis. Its pipeline includes long-acting atovaquone for malaria prophylaxis, as well as candidate formulations for hepatitis C and latent tuberculosis. The company focuses on treatments that can be deployed in both low-to-middle-income and high-income healthcare settings. It collaborates with academic and global health partners to advance and evaluate its formulations.
